Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT

Ovarian preservation during the surgical treatment of early stage endometrial cancer: A nation-wide study conducted by the Korean Gynecologic Oncology Group

“…Although available evidence supporting the benefit of intraoperative frozen biopsy to helpfully rule out an adnexal pathology is limited, its clinical value is worthy of study [23]. Furthermore, PET/CT advancements might also provide a means of predicting occult metastasis [24,25]. However, several issues remain to be resolved, such as, its low sensitivity for small occult lesions and its false positivity due to physiologic uptake [26,27].…”

18F-FDG PET/CT Imaging In Oncology

“…There is no role for 18 F-FDG PET/CT in early cutaneous melanoma (American Joint Committee on Cancer stages I and II) 126127. In advanced (AJCC stages III and IV) and recurrent cutaneous melanoma, 18 F-FDG PET shows 100% sensitivity for visceral and abdominal nodal metastases and 100% accuracy for superficial lymph node metastases, but lower sensitivity for pulmonary metastases 128.…”

The Role of 18F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries

“…18 F-FDG PET and 18 F-FDG PET/CT may be especially useful for the selection of patients with late recurrent disease who may benefit from secondary cytoreductive surgery (51). A prospective study of 22 patients with elevated CA-125 and negative or equivocal CT findings evaluated the ability of PET to detect macroscopic disease that can potentially be resected surgically.…”